Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Soligenix, Inc. - Common Stock (NQ:SNGX)

2.800 -0.120 (-4.11%)
Streaming Delayed Price Updated: 1:01 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Soligenix, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Soligenix Inc. (NASDAQ: SNGX) Showcases Expanding Rare Disease, Public Health Pipeline in Latest Corporate Presentation
Via Investor Brand Network
Senior NIH Officials Allege Retaliation as Motive for Their Ouster
Via Investor Brand Network
Topics Whistleblower
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Publishes Data Demonstrating Two-Year Stability of ThermoVax Ebolavirus Vaccines
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Treatment with FDA Orphan Designation
Via Investor Brand Network
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) CEO to Present at H.C. Wainwright Global Investment Conference
Via Investor Brand Network
Study Explains Why Blood Clotting is Common in IBD Patients
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Reports Major Clinical Trial Milestones, Strategic Progress in Rare Disease Treatment Pipeline
Via Investor Brand Network
Synergy Corp. (NASDAQ: SNYR) 1,600+ Nationwide Store Rollout – PPCB, SNGX, BTAI, HIT + Other Disruptive Stocks Moving Now!
Via AB Newswire
Topics Artificial Intelligence
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Awarded FDA Orphan Drug Designation for Dusquetide in Behçet’s Disease
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy
Via Investor Brand Network
Study Finds That Low BSA Psoriasis Could Have a High Disease Burden
Via Investor Brand Network
BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Q2 2025 Results Highlight Progress in Late-Stage Rare Disease Pipeline
Via Investor Brand Network
InvestorNewsBreaks – Alliance Global Partners Maintains Buy Rating, Increases Price Target as Soligenix Inc. (NASDAQ: SNGX) Advances Proprietary Clinical Programs
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Featured in NNW Editorial on Rare Disease Innovation
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy
From Soligenix, Inc.
Via GlobeNewswire
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
Via Investor Brand Network
Topics Government
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
EQNX::TICKER_START (NASDAQ:SNGX),(NASDAQ:FOLD),(NASDAQ:TNXP),(NASDAQ:CTOR),(NASDAQ:AMGN) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Government
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Editorial on Rare Disease Therapeutics
Via Investor Brand Network
Study Finds That Inflammation Markers in Diabetics Influence Depression Treatment Outcomes
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
From Soligenix, Inc.
Via GlobeNewswire
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
Via Investor Brand Network
Topics Government
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
EQNX::TICKER_START (NASDAQ:SNGX),(NYSE:PFE),(NYSE:MRK),(NYSE:BMY),(NASDAQ:INSM) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Government
Loop Industries (Nasdaq: LOOP) Unveils Game-Changing Twist™ Polyester Made Entirely from Textile Waste – More Stocks Inside
Via AB Newswire
Topics Economy Emissions Energy
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Achieves Biological Efficacy in Phase 2a SGX945 Study for Behçet’s Disease
Via Investor Brand Network
BioMedNewsBreaks — Targeting the Unmet: Soligenix Inc. (NASDAQ: SNGX) Building Portfolio for Rare Conditions
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Pioneering Oral Mucositis Treatment with Novel Therapeutic, Promising Study Results
Via Investor Brand Network
Global Vaccination Goals at Risk as 14 Million Kids Miss Crucial Shots
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Reports Strong Results in ‘Real-World’ Trial
Via Investor Brand Network
InvestorNewsBreaks – Zacks Research Releases Updated Report as Soligenix Inc. (NASDAQ: SNGX) Eyes Upcoming ‘Key Catalysts’
Via Investor Brand Network
Dutch Startup Develops Highly Sensitive Field Test for Infectious Diseases
Via Investor Brand Network
Topics Climate Change
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.